Published in N Engl J Med on September 12, 2002
Radical prostatectomy or watchful waiting in early prostate cancer. N Engl J Med (2014) 10.06
Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. J Natl Cancer Inst (2008) 8.62
The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. J Clin Oncol (2004) 5.09
Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Oncogene (2007) 4.81
Gene expression profiling predicts clinical outcome of prostate cancer. J Clin Invest (2004) 4.59
Long-term outcome among men with conservatively treated localised prostate cancer. Br J Cancer (2006) 2.76
Race/ethnicity and the receipt of watchful waiting for the initial management of prostate cancer. J Gen Intern Med (2004) 1.97
Prostate-specific antigen testing among the elderly in community-based family medicine practices. J Am Board Fam Med (2009) 1.76
Local progression among men with conservatively treated localized prostate cancer: results from the Transatlantic Prostate Group. Eur Urol (2007) 1.60
Robotic prostatectomy: The new standard of care or a marketing success? Can Urol Assoc J (2009) 1.42
Factors associated with initial treatment and survival for clinically localized prostate cancer: results from the CDC-NPCR Patterns of Care Study (PoC1). BMC Cancer (2010) 1.41
Current status of PSA screening. Early detection of prostate cancer. Can Fam Physician (2004) 1.39
Pattern of prostate-specific antigen (PSA) failure dictates the probability of a positive bone scan in patients with an increasing PSA after radical prostatectomy. J Clin Oncol (2005) 1.35
Molecular mapping of tumor heterogeneity on clinical tissue specimens with multiplexed quantum dots. ACS Nano (2010) 1.31
Racial differences in initial treatment for clinically localized prostate cancer. Results from the prostate cancer outcomes study. J Gen Intern Med (2003) 1.30
Testing a multigene signature of prostate cancer death in the Swedish Watchful Waiting Cohort. Cancer Epidemiol Biomarkers Prev (2008) 1.26
Prostate cancer screening: current status and future perspectives. Nat Rev Urol (2010) 1.23
Active surveillance for prostate cancer: patient selection and management. Curr Oncol (2010) 1.22
What's a man to do? Treatment options for localized prostate cancer. Can Fam Physician (2004) 1.18
Anesthesia considerations for robotic-assisted laparoscopic prostatectomy: a review of 1,500 cases. J Robot Surg (2007) 1.05
Hsp-27 expression at diagnosis predicts poor clinical outcome in prostate cancer independent of ETS-gene rearrangement. Br J Cancer (2009) 1.04
Radiation dose and late failures in prostate cancer. Int J Radiat Oncol Biol Phys (2006) 1.01
Surgery and the reduction of mortality from prostate cancer. N Engl J Med (2002) 0.97
Radical prostatectomy as treatment for prostate cancer. CMAJ (2003) 0.96
The use of interim data and Data Monitoring Committee recommendations in randomized controlled trial reports: frequency, implications and potential sources of bias. BMC Med Res Methodol (2008) 0.96
Prognostic determinants in prostate cancer. Cancer J (2011) 0.95
Oral selenium supplementation has no effect on prostate-specific antigen velocity in men undergoing active surveillance for localized prostate cancer. Cancer Prev Res (Phila) (2010) 0.92
Results from the Scandinavian Prostate Cancer Group Trial Number 4: a randomized controlled trial of radical prostatectomy versus watchful waiting. J Natl Cancer Inst Monogr (2012) 0.88
Agreement between prostate cancer patients and their clinicians about utilities and attribute importance. Health Expect (2004) 0.88
Association of prostate cancer and manganese superoxide dismutase AA genotype influenced by presence of occult cancer in control group. Urology (2008) 0.87
The cost-utility of open prostatectomy compared with active surveillance in early localised prostate cancer. BMC Health Serv Res (2014) 0.87
STAT3 inhibition in prostate and pancreatic cancer lines by STAT3 binding sequence oligonucleotides: differential activity between 5' and 3' ends. Mol Cancer Ther (2008) 0.86
Radiotherapy and survival in prostate cancer patients: a population-based study. Int J Radiat Oncol Biol Phys (2008) 0.86
African American men, prostate cancer screening and informed decision making. J Natl Med Assoc (2003) 0.86
Survival of prostate cancer patients in central and northern Denmark, 1998-2009. Clin Epidemiol (2011) 0.86
Gleason score and pretreatment prostate-specific antigen in survival among patients with stage D2 prostate cancer. World J Urol (2004) 0.85
High-intensity focused ultrasound for prostate cancer: long-term followup and complications rate. Adv Urol (2012) 0.85
Managing the low-socioeconomic-status prostate cancer patient. J Natl Med Assoc (2006) 0.85
Prostate cancer management: (1) an update on localised disease. Postgrad Med J (2003) 0.85
Erectile preservation following radical prostatectomy. Ther Adv Urol (2011) 0.85
The roulette wheel: an aid to informed decision making. PLoS Med (2006) 0.85
Diagnosis of prostate cancer by detection of minichromosome maintenance 5 protein in urine sediments. Br J Cancer (2010) 0.83
Prostate cancer: epidemiology and screening. Rev Urol (2003) 0.83
Can a single model explain both breast cancer and prostate cancer? Theor Biol Med Model (2007) 0.83
Improved detection of circulating tumor cells in non-metastatic high-risk prostate cancer patients. Sci Rep (2016) 0.82
Surgical versus medical castration in the Bahamas: a male macho paradox. Infect Agent Cancer (2009) 0.82
Occult prostate cancer effects the results of case-control studies due to verification bias. Anticancer Res (2008) 0.82
Focal therapy in prostate cancer: the current situation. Ecancermedicalscience (2014) 0.82
Prostate-specific antigen screening and mortality from prostate cancer. J Gen Intern Med (2008) 0.81
Managed care market share and primary treatment for cancer. Health Serv Res (2006) 0.81
Screening for aortic aneurysm. Human cost should not be dismissed. BMJ (2003) 0.80
The utility of a multimedia education program for prostate cancer patients: a formative evaluation. Br J Cancer (2004) 0.80
The comparative oncologic effectiveness of available management strategies for clinically localized prostate cancer. Urol Oncol (2016) 0.80
Benign prostate glandular tissue at radical prostatectomy surgical margins. Urology (2013) 0.79
ProCOC: the prostate cancer outcomes cohort study. BMC Urol (2008) 0.78
Correlation of endorectal coil magnetic resonance imaging of the prostate with pathologic stage. World J Urol (2004) 0.78
Can a Gleason 6 or Less Microfocus of Prostate Cancer in One Biopsy and Prostate-Specific Antigen Level <10 ng/mL Be Defined as the Archetype of Low-Risk Prostate Disease? J Oncol (2012) 0.78
3D proton MR spectroscopic imaging of prostate cancer using a standard spine coil at 1.5 T in clinical routine: a feasibility study. Eur Radiol (2004) 0.78
Survival in prostate cancer patients > or = 70 years after radical prostatectomy and comparison to younger patients. World J Urol (2009) 0.77
DO CANCER CLINICAL TRIAL POPULATIONS TRULY REPRESENT CANCER PATIENTS? A COMPARISON OF OPEN CLINICAL TRIALS TO THE CANCER GENOME ATLAS. Pac Symp Biocomput (2016) 0.77
Age and Racial Differences among PSA-Detected (AJCC Stage T1cN0M0) Prostate Cancer in the U.S.: A Population-Based Study of 70,345 Men. Front Oncol (2013) 0.77
A national survey of medical students' beliefs and knowledge in screening for prostate cancer. J Gen Intern Med (2007) 0.77
Does early resection of presumed low-grade glioma improve survival? A clinical perspective. J Neurooncol (2017) 0.76
Prostate biopsy sampling causes hematogenous dissemination of epithelial cellular material. Dis Markers (2014) 0.75
Prostatectomy or watchful waiting in prostate cancer. N Engl J Med (2003) 0.75
Prostate cancer (early). BMJ Clin Evid (2006) 0.75
Economic evaluation of treatments for patients with localized prostate cancer in Europe: a systematic review. BMC Health Serv Res (2016) 0.75
TMPRSS2:ERG gene aberrations may provide insight into pT stage in prostate cancer. BMC Urol (2016) 0.75
Multigene panels in prostate cancer risk assessment: a systematic review. Genet Med (2015) 0.75
A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. J Urol (2003) 0.75
First danish single-institution experience with radical prostatectomy: biochemical outcome in 1200 consecutive patients. Prostate Cancer (2010) 0.75
Effect of intervention on decision making of treatment for disease progression, prostate-specific antigen biochemical failure and prostate cancer death. Health Expect (2012) 0.75
Prostatectomy or watchful waiting in prostate cancer. N Engl J Med (2003) 0.75
ESTIMATING PERSON-CENTERED TREATMENT (PeT) EFFECTS USING INSTRUMENTAL VARIABLES: AN APPLICATION TO EVALUATING PROSTATE CANCER TREATMENTS. J Appl Econ (Chichester Engl) (2015) 0.75
Radical prostatectomy may improve disease-specific mortality, but not overall survival compared with watchful waiting in early prostate cancer. Cancer Treat Rev (2003) 0.75
In patients with early prostate cancer, is surgery better than watchful waiting? CMAJ (2005) 0.75
Prostatectomy or watchful waiting in prostate cancer. N Engl J Med (2003) 0.75
Prostatectomy or watchful waiting in prostate cancer. N Engl J Med (2003) 0.75
Prostate cancer screening: why it's not for every man. Medscape J Med (2008) 0.75
Contemporary update of cancer control after radical prostatectomy in the UK. Br J Cancer (2004) 0.75
Management of localized prostate cancer. Rev Urol (2004) 0.75
Early radical prostatectomy improves disease-specific but not overall survival. J Fam Pract (2003) 0.75
Expectant management of prostate cancer. Rev Urol (2003) 0.75
Prostatectomy or watchful waiting in prostate cancer. N Engl J Med (2003) 0.75
[Radiotherapy for prostate cancer]. Wien Med Wochenschr (2007) 0.75
Priorities in future research in prostate cancer screening. Eur J Epidemiol (2003) 0.75
[The hormone refractory prostate cancer - a challenge for the internal specialist]. Wien Med Wochenschr (2007) 0.75
Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med (2005) 16.35
Cumulative association of five genetic variants with prostate cancer. N Engl J Med (2008) 15.34
A common variant associated with prostate cancer in European and African populations. Nat Genet (2006) 13.47
Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med (2011) 13.30
Radical prostatectomy or watchful waiting in early prostate cancer. N Engl J Med (2014) 10.06
Effect of screening mammography on breast-cancer mortality in Norway. N Engl J Med (2010) 8.71
Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. J Natl Cancer Inst (2008) 8.62
Overdiagnosis of invasive breast cancer due to mammography screening: results from the Norwegian screening program. Ann Intern Med (2012) 7.78
Natural history of early, localized prostate cancer. JAMA (2004) 7.44
Quality of life after radical prostatectomy or watchful waiting. N Engl J Med (2002) 6.83
The enigmatic epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev (2006) 6.61
Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer. Nat Genet (2008) 6.10
Long-term quality-of-life outcomes after radical prostatectomy or watchful waiting: the Scandinavian Prostate Cancer Group-4 randomised trial. Lancet Oncol (2011) 5.28
Long-term colorectal-cancer mortality after adenoma removal. N Engl J Med (2014) 5.05
Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP. J Natl Cancer Inst (2007) 4.85
Non-communicable diseases in sub-Saharan Africa: what we know now. Int J Epidemiol (2011) 4.74
Low carbohydrate-high protein diet and incidence of cardiovascular diseases in Swedish women: prospective cohort study. BMJ (2012) 4.05
Oral use of Swedish moist snuff (snus) and risk for cancer of the mouth, lung, and pancreas in male construction workers: a retrospective cohort study. Lancet (2007) 3.84
Effect of low doses of ionising radiation in infancy on cognitive function in adulthood: Swedish population based cohort study. BMJ (2004) 3.67
The Swedish Twin Registry in the third millennium: an update. Twin Res Hum Genet (2006) 3.58
Suicide and cardiovascular death after a cancer diagnosis. N Engl J Med (2012) 3.56
Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. J Natl Cancer Inst (2008) 3.55
Epidemiology and etiology of Parkinson's disease: a review of the evidence. Eur J Epidemiol (2011) 3.45
The non-Hodgkin lymphomas: a review of the epidemiologic literature. Int J Cancer (2007) 3.44
Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology (2005) 3.40
A prospective study of pigmentation, sun exposure, and risk of cutaneous malignant melanoma in women. J Natl Cancer Inst (2003) 3.29
Ultraviolet radiation exposure and risk of malignant lymphomas. J Natl Cancer Inst (2005) 3.19
Evidence for two independent prostate cancer risk-associated loci in the HNF1B gene at 17q12. Nat Genet (2008) 3.14
Long-term distress after radical prostatectomy versus watchful waiting in prostate cancer: a longitudinal study from the Scandinavian Prostate Cancer Group-4 randomized clinical trial. Eur Urol (2013) 2.84
Risk of ovarian cancer in breast-cancer patients with a family history of breast or ovarian cancer: a population-based cohort study. Lancet (2002) 2.72
Trends in incidence and mortality of nasopharyngeal carcinoma over a 20-25 year period (1978/1983-2002) in Sihui and Cangwu counties in southern China. BMC Cancer (2006) 2.71
Individualized estimation of the benefit of radical prostatectomy from the Scandinavian Prostate Cancer Group randomized trial. Eur Urol (2012) 2.62
Risk of thromboembolic diseases in men with prostate cancer: results from the population-based PCBaSe Sweden. Lancet Oncol (2010) 2.56
Average energy intake among pregnant women carrying a boy compared with a girl. BMJ (2003) 2.55
Prostate-specific antigen levels as a predictor of lethal prostate cancer. J Natl Cancer Inst (2007) 2.49
Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer. J Clin Oncol (2011) 2.46
Outcomes in localized prostate cancer: National Prostate Cancer Register of Sweden follow-up study. J Natl Cancer Inst (2010) 2.45
Molecular sampling of prostate cancer: a dilemma for predicting disease progression. BMC Med Genomics (2010) 2.40
Genome-wide association study of follicular lymphoma identifies a risk locus at 6p21.32. Nat Genet (2010) 2.37
Sector resection with or without postoperative radiotherapy for stage I breast cancer: 20-year results of a randomized trial. J Clin Oncol (2014) 2.35
Natural history of early, localized prostate cancer: a final report from three decades of follow-up. Eur Urol (2012) 2.28
Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype. J Natl Cancer Inst (2006) 2.23
The socioeconomic gradient in the incidence of stroke: a prospective study in middle-aged women in Sweden. Stroke (2006) 2.23
How well does the Gleason score predict prostate cancer death? A 20-year followup of a population based cohort in Sweden. J Urol (2006) 2.21
Meat and dairy food consumption and breast cancer: a pooled analysis of cohort studies. Int J Epidemiol (2002) 2.19
Immediate risk of suicide and cardiovascular death after a prostate cancer diagnosis: cohort study in the United States. J Natl Cancer Inst (2010) 2.18
Surveillance and deferred treatment for localized prostate cancer. Population based study in the National Prostate Cancer Register of Sweden. J Urol (2008) 2.17
Interpreting trends in prostate cancer incidence and mortality in the five Nordic countries. J Natl Cancer Inst (2007) 2.08
HLA-A confers an HLA-DRB1 independent influence on the risk of multiple sclerosis. PLoS One (2007) 2.05
Estimation of absolute risk for prostate cancer using genetic markers and family history. Prostate (2009) 1.99
Genome-wide association study of classical Hodgkin lymphoma and Epstein-Barr virus status-defined subgroups. J Natl Cancer Inst (2012) 1.99
A prospective study of body size in different periods of life and risk of premenopausal breast cancer. Cancer Epidemiol Biomarkers Prev (2004) 1.97
Clinical characteristics and primary treatment of prostate cancer in Sweden between 1996 and 2005. Scand J Urol Nephrol (2007) 1.93
Sequence variants of toll-like receptor 4 are associated with prostate cancer risk: results from the CAncer Prostate in Sweden Study. Cancer Res (2004) 1.91